» Articles » PMID: 26853128

International Consensus on Allergen Immunotherapy II: Mechanisms, Standardization, and Pharmacoeconomics

Abstract

This article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT cost-effectiveness, and regulatory guidance. Potential barriers to and facilitators of the use of AIT are described in addition to future directions. International allergy specialists representing the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the World Allergy Organization critically reviewed the existing literature and prepared this summary of recommendations for best AIT practice. The authors contributed equally and reached consensus on the statements presented herein.

Citing Articles

Adjuvant Effect of in Sublingual Immunotherapy of Asthmatic Mice.

Alwayli D, Jiang X, Liang J, Shah S, Ullah A, Abusidu M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770422 PMC: 11678203. DOI: 10.3390/ph17121580.


Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.

Li K, Jin J, Yang Y, Luo X, Wang Y, Xu A Int J Nanomedicine. 2024; 19:12015-12037.

PMID: 39583318 PMC: 11584337. DOI: 10.2147/IJN.S484327.


Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis.

Hoshino M, Akitsu K, Ohtawa J, Kubota K J Allergy Clin Immunol Glob. 2024; 3(2):100206.

PMID: 38328802 PMC: 10847160. DOI: 10.1016/j.jacig.2024.100206.


IgG in the control of FcεRI activation: a battle on multiple fronts.

Storni F, Vogel M, Bachmann M, Engeroff P Front Immunol. 2024; 14:1339171.

PMID: 38274816 PMC: 10808611. DOI: 10.3389/fimmu.2023.1339171.


Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis: Post hoc analysis of a large phase 3 trial.

Pfaar O, de Blay F, Canonica G, Casale T, Gevaert P, Hellings P World Allergy Organ J. 2024; 17(1):100849.

PMID: 38225952 PMC: 10788274. DOI: 10.1016/j.waojou.2023.100849.